Enveric Biosciences Inc. (ENVB)
| Bid | 1.23 |
| Market Cap | 3.22M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.57M |
| EPS (ttm) | -19.04 |
| PE Ratio (ttm) | -0.07 |
| Forward PE | -0.05 |
| Analyst | Buy |
| Ask | 1.27 |
| Volume | 35,496 |
| Avg. Volume (20D) | 2,779,504 |
| Open | 1.28 |
| Previous Close | 1.32 |
| Day's Range | 1.23 - 1.34 |
| 52-Week Range | 1.01 - 231.75 |
| Beta | 0.34 |
About ENVB
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosc...
Analyst Forecast
According to 1 analyst ratings, the average rating for ENVB stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 666.64% from the latest price.
Stock Forecasts
2 months ago · businesswire.com
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. PatentCAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therap...
2 months ago · businesswire.com
Enveric Biosciences Announces Closing of $5 Million Public OfferingCAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule ...